Francis Lun, Managing Director at Lyncean Holdings says Hong Kong's IPO market is in a deep recession, hurt by a slump in China and the euro zone. He adds the market's recovery will be slow.
TheStreet.com reports on Sarepta Therapeutics and the outstanding results from the eteplirsen study in Duchenne muscular dystrophy announced today.
Thanks to several rounds of cost cutting and new product launches, cash balances across the pharma sector are increasing — because one analyst said we should see more cash being returned to shareholders via dividend.
CNBC's Seema Mody shares several dividend plays for investors seeking yield in the pharma sector.
TheStreet reports that Peregrine stock plunged when company reported discrepancies in the cancer drug bavituximab study.
Savient Pharmaceuticals has been taken to the woodshed, but recently it’s turned bullish.
Vivus announced the commercial launch of its weight-loss pill Qsymia Monday, beating rival Arena Pharmaceuticals to first reach the bulging waistbands of obese Americans. TheStreet.com reports.
Option action lit up yesterday in Abbott Laboratories, which has been a solid performer for the last year.
AstraZeneca has appointed Pascal Soriot, former chief executive of Genentech, as its new chief executive following the departure of David Brennan earlier this year.
Idenix Pharmaceuticals shares fell 10 percent Monday after the U.S. Food and Drug Administration placed a second of the company's experimental hepatitis C drugs on clinical hold due to heart safety concerns. TheStreet.com reports.
A treatment for Alzheimer's disease from drugmaker Eli Lilly yielded promising signs in late-stage research, even though the drug failed to slow mental decline in two separate studies of patients with mild-to-moderate cases of the mind-robbing condition.
Now is the time to own stocks with big dividends, one analyst says. In health care, that means large cap pharmaceuticals. TheStreet.com reports.
Apple has quietly told its store workers to match discounts on the iPhone 4 and iPhone 4S from approved major retailers and carriers like Sprint Nextel, which is currently offering a $50 break. Apple won’t offer the discounts automatically; customers have to ask.
Think you can’t own growth stocks in this market? Think again.
FBI agents arrested Robert Ramnarine, a Bristol-Myers Squibb executive, on Thursday, and criminally charged him with insider trading in call options, court papers show.
Bristol-Myers Squibb suspended a mid-stage study of its experimental hepatitis C drug BMS-094 due to a serious safety issue — a major blow to the company’s research pipeline that is also likely to rejigger the way Wall Street views other companies’ efforts to develop an all-oral therapy against the viral liver disease.
Large regional banks continue to outperform the money center banks, despite the compelling stock price multiples for the largest bank holding companies.
Horizon Pharma should hear good news from U.S. regulators Thursday about its rheumatoid arthritis drug Rayos. Full approval of the drug should be in the bag.
Generic competition will be the major headwind that Bristol-Myers Squibb faces this quarter, as its blockbuster drug Plavix — which saw U.S. sales peak at $7 billion last year — went off patent in May.
Biotech earnings kick off tomorrow, with Biogen reporting pre-market. Biotech has been an exciting space to watch with the sector outperforming the major indices.